Su1374 Low Dose Azathioprine With Allopurinol Co-Therapy Without Metabolite Profiling Is More Effective and Safer Than Full Dose Azathioprine for Inflammatory Bowel Disease Patients: A Large UK Centre Experience

2014 ◽  
Vol 146 (5) ◽  
pp. S-450-S-451 ◽  
Author(s):  
Panagiotis Stamoulos ◽  
Evangelos Stournaras ◽  
Clare Bull ◽  
Matthew Cowan ◽  
Gary Mackenzie ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Metabolite Profiling ◽  
Low Dose ◽  
Full Dose ◽  
Inflammatory Bowel

scholarly journals Su1862 – Low-Dose Methotrexate is Equally Effective As High-Dose in Combination with Anti-TNF Therapy in Inflammatory Bowel Disease

2019 ◽  
Vol 156 (6) ◽  
pp. S-639-S-640
Author(s):  
Nienke Z. Borren ◽  
Jay Luther ◽  
Francis Colizzo ◽  
John J. Garber ◽  
Hamed Khalili ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Low Dose ◽  
High Dose ◽  
Dose Methotrexate ◽  
Inflammatory Bowel

P-132 YI Experience with Low-Dose Mycophenolate for the Inflammatory Bowel Disease Population

2013 ◽  
Vol 19 ◽  
pp. S76-S77
Author(s):  
Benjamin Hall ◽  
Rinjal Brahmbhatt ◽  
Terrence Frick ◽  
Mark Reichelderfer ◽  
Sumona Saha
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Low Dose ◽  
Inflammatory Bowel

Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease

2018 ◽  
Vol 50 (7) ◽  
pp. 682-688 ◽  
Author(s):  
Abhinav Vasudevan ◽  
Lauren Beswick ◽  
Antony B. Friedman ◽  
Alicia Moltzen ◽  
James Haridy ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Low Dose ◽  
Inflammatory Bowel

scholarly journals A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients

2020 ◽  
Vol 51 (11) ◽  
pp. 1076-1086
Author(s):  
Vince B. C. Biemans ◽  
Edo Savelkoul ◽  
Ruben Y. Gabriëls ◽  
Melek Simsek ◽  
Gerard Dijkstra ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Comparative Analysis ◽  
Bowel Disease ◽  
Low Dose ◽  
Inflammatory Bowel

scholarly journals A murine model of pediatric inflammatory bowel disease causes microbiota-gut-brain axis deficits in adulthood

2020 ◽  
Vol 319 (3) ◽  
pp. G361-G374 ◽  
Author(s):  
Eloisa Salvo ◽  
Patricia Stokes ◽  
Ciara E. Keogh ◽  
Ingrid Brust-Mascher ◽  
Carly Hennessey ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Early Life ◽  
Low Dose ◽  
Behavioral Deficits ◽  
Colonic Inflammation ◽  
Gut Dysbiosis ◽  
Pediatric Inflammatory Bowel Disease ◽  
Adult Mice ◽  
Inflammatory Bowel

Here we describe long-lasting impacts on the microbiota-gut-brain (MGB) axis following administration of low-dose dextran sodium sulfate (DSS) to weaning mice (P21), including gut dysbiosis, colonic inflammation, and brain/behavioral deficits in adulthood (P56). Early-life DSS leads to acute colonic inflammation, similar to adult mice; however, it results in long-lasting deficits in the MGB axis in adulthood (P56), in contrast to the transient deficits seen in adult DSS. This model highlights the unique features of pediatric inflammatory bowel disease.

Sign in / Sign up

Export Citation Format

Share Document